South Korea drug pricing and reimbursement: key facts

Last updated 2026-11-16 · 10 sourced answers from KIRA RESEARCH reports and field research. Every figure shows its year and source.

Channels and distribution

Where do generic drug makers win sales in Korea, clinics or hospitals?

Clinics favour generic-led firms with large, well-trained rep forces and low prices, while established firms target general and university hospitals, per KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul).

Source: KIRA field research (modelled interview), 2026 · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original

Is national reimbursement listing enough to get a new drug onto hospital formularies in Korea?

No: each hospital's drug committee adds a product to its formulary separately, and price influences inclusion, per KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul).

Source: KIRA field research (modelled interview), 2026 · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original

Which hospitals tend to become a new drug's first formulary wins in Korea?

Hospitals hosting a maker's clinical trial tend to become its first formulary wins, and reps later use the hospital's name, per KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul).

Source: KIRA field research (modelled interview), 2026 · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original

Pricing

Does a price request get more scrutiny in Korea's drug price review?

Officials look hard at expensive filings, while a filing asking for a reasonable price usually passes without a second review, per KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul).

Source: KIRA field research (modelled interview), 2026 · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original

Regulation

Can a foreign importer expect the modified-drug price premium in Korea, and for how long?

Importers should not expect the premium local producers keep; the term is 1 year, extended 2 years at a time (Dailypharm, 6 May 2026), as cited in KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul).

Source: KIRA field research (modelled interview), 2026 · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original

Market entry

What does a late generic entrant face in Korea once many copies are listed?

Being a late entrant at the lowest list price, without a strong rep force, is a listing rather than a business, per KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul).

Source: KIRA field research (modelled interview), 2026 · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original

What should a foreign drug maker without hospital coverage do before launching in Korea?

Firms without hospital coverage or a rep force should find a partner before launch, not after, per KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul).

Source: KIRA field research (modelled interview), 2026 · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original

Risks

What do originators do when local copies arrive after patent expiry in Korea?

Many local copies arrive within months; originators defend with outcome data, new strengths or indications and selective price cuts, per KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul).

Source: KIRA field research (modelled interview), 2026 · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original

How the trade works

How has drug promotion to doctors in Korea changed after official warnings?

After official warnings over illegal support to prescribers, firms cut sponsorship and leaned on clinical data in promotion, per KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul).

Source: KIRA field research (modelled interview), 2026 · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original

How is a generic drug's reimbursement price checked in Korea?

Reviewers check a generic's price against ministry rules using the company's documents, with little capacity to re-check each number, per KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul).

Source: KIRA field research (modelled interview), 2026 · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original

Who decides

Practitioner views from KIRA Experts transcripts: modelled interviews built on KIRA's field interviews. How we work: Methodology.

Who specifies

  • Doctors' acceptance of a modified copy of a leading molecule depends on local clinical data and on the hospital formulary decision. former reimbursement pricing official now advising drug makers on listings · KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul)
  • Companies hire managers with past regulator experience because they are seen to help approval, listing and promotion. former reimbursement pricing official now advising drug makers on listings · KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul)

Who buys and pays

  • When a low-price product stops making money, the company quietly stops producing rather than arguing about the price. former reimbursement pricing official now advising drug makers on listings · KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul)
  • The company carries the consequence of its own filing: a missing drug-substance certificate is not debated but leads to a lower price. former reimbursement pricing official now advising drug makers on listings · KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul)

Who carries the risk

No field statement yet

How the trade works

Practitioner views from KIRA Experts transcripts: modelled interviews built on KIRA's field interviews. How we work: Methodology.